Background

Joseph is a physician and researcher with a particular interest in the epidemiology, management and prevention of blood borne viruses (HIV, hepatitis C and hepatitis B).

With a background in clinical medicine, Joseph specialised in infectious diseases at the Alfred where he works as a consultant physician. He completed his MPH at the London School of Hygiene and Tropical Medicine and his public health fellowship was undertaken at the Victorian Infectious Diseases Reference Laboratory and Burnet Institute. His PhD at Burnet and Monash School of Population Health was focused on the effectiveness of early hepatitis C treatment.

Joseph is currently undertaking his NHMRC Postdoctoral Fellowship aiming to improve population health and treatment for hepatitis C infection at Burnet and Department of Infectious Diseases at Monash University. He is co-head of Viral Hepatitis Research and the clinical director of the hepatitis C TAP (Treatment and Prevention Study) at Burnet.

Appointments

• Deputy Program Director, Disease Elimination, Burnet Institute
• Co-Head, Viral Hepatitis Elimination, Burnet Institute
• NHMRC Clinical Research Fellow, Monash University
• Senior Research Fellow, Department of Infectious Diseases, Monash University
• Honorary Research Fellow, Department of Gastroenterology, St Vincent’s Hospital Melbourne
• Adjunct Senior Lecturer, School of Population Health and Preventive Medicine, Monash University
• Consultant Infectious Diseases Physician, The Alfred Hospital, Victoria, Australia

Positions

• 2015-2016: Postdoctoral Fellowship, Department of Gastroenterology, St Vincent’s Hospital and University of Melbourne
• 2011-2014: PhD Candidate, Burnet Institute, Centre for Population Health
• 2008-2011: Infectious Diseases Fellowship undertaken at the Royal Melbourne, Alfred and St Vincent’s Hospitals, and the Victorian Infectious Diseases Reference Laboratory, Victoria, Australia

Qualifications

• 2015: PhD, Monash University
• 2014: FAFPHM, Fellow of Australasian Faculty of Public Health Medicine, Australia
• 2011: FRACP in Infectious Diseases, Fellow of Royal Australasian College of Physicians, Australia
• 2006: MPH, London School of Hygiene and Tropical Medicine, United Kingdom
• 2005: BA (Hons), Department of Political Science, University of Melbourne, Victoria, Australia
• 2002: MBBS, University of Melbourne, Australia

Awards

• 2017: Burnet Institute Gust-McKenzie Medal
• 2014: NHMRC Early Career Fellowship
• 2011: NHMRC Postgraduate Scholarship

Projects (22)

Current (15)

• 

  Barriers to hepatocellular carcinoma screening uptake in Victoria

• 

  Cancer information compared to Hepatitis B information to INcreAse hepatitis B testing in Melbourne’s Chinese community (CHINA-B study)

• 

  co-EC Study: Eliminating hepatitis C/HIV coinfection

• 

  DARE C: ATAHC II Substudy

• 

  EC Australia: Eliminate Hepatitis C Australia Partnership

• 

  EC Partnership: Eliminate Hepatitis C Partnership

• 

  National COVID-19 Clinical Evidence Taskforce

• 

  Natural history and response to treatment recent hepatitis C virus infection among a cluster of HCV genotype-1b infected individuals

• 

  Optimising Quarantine Study

• 

  The elimination of hepatitis C as a global public health threat

• 

  The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

• 

  The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19

• 

  The PharmEC REACH study

• 

  The QuickStart Study

• 

  What drives hepatitis C reinfection?

Past (3)

• 

  Eliminating hepatitis C infection in Victoria through treatment scale up

• 

  Examining hepatitis C reinfection among HIV co-infected gay and bisexual men

• 

  Hepatitis B infection in Australian prisons

Publications (106)

2022 (6)

• Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).
  O'Keefe D, Gunn J, Ryan K, Djordjevic F, Kerr P, Gold J, Elsum I, Layton C, Chan K, Dietze P, Higgs P, Doyle J, Stoové MA, Hellard M, Pedrana AE
  BMJ Open. 2022 Jan; 12(1):e057618
• High effectiveness of broad access direct-acting antiviral therapy for hepatitis C in an Australian real-world cohort: The REACH-C Study
  Yee J, Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Doyle JS, Davies J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group.
  Hepatol Commun. 2022 Jan; Epub ahead of print
• A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
  Harney BL, Whitton B, Paige E, Brereton R, Weiss R, Membrey D, Wade AJ, Iser D, Kemp W, Roberts SK, Spelman T, Sacks-Davis R, Hellard ME, Doyle JS
  Liver Int. 2022 Jan; Epub ahead of print
• The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019.
  Harney BL, Sacks-Davis R, van Santen DK, Traeger M, Wilkinson AL, Asselin J, El-Hayek C, Fairley CK, Roth N, Bloch M, Matthews G, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS; Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood-borne Viruses (ACCESS).
  Clin Infect Dis. 2022 Jan; Epub ahead of print
• Screening for risky drinkers among hospitalised inpatients using the AUDIT: A feasibility, point prevalence and data linkage study.
  O'Brien H, Di Rico R, Dean E, Smoker G, Lloyd-Jones M, McKechnie M, Dietze PM, Doyle JS
  Drug Alcohol Rev. 2022 Jan; Epub ahead of print
• Assessment of the cost-effectiveness of Australia’s risksharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.
  Scott N, Palmer MA, Tidhar MT, Stoové M, Sacks-Davis R, Doyle JS, Pedrana A, Thompson AJ, Wilson DP, Hellard M
  Lancet Reg Health - West Pac. 2022 Jan; 18:100316

2021 (18)

• Assessing the feasibility, acceptability and impacts of an education program on hepatitis B testing uptake among ethnic Chinese in Australia: results of a randomised controlled pilot study.
  Xiao Y, Wallace J, Ahad M, van Gemert C, Thompson AJ, Doyle J, Lam HY, Chan K, Bennett G, Adamson E, Yussf N, Tang A, Pedrana A, Stoove M, Hellard M, Howell J
  BMC Public Health. 2021 Oct; 21(1):1861
• Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort.
  Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Davies J, Doyle JS, Yee J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group
  Int J Drug Policy. 2021 Oct; 96:103422
• Letter in response: Psychiatrists can treat hepatitis C.
  Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS
  J Viral Hepat. 2021 Sep; 28(12):1765+1766
• Early antimicrobial stewardship team intervention on appropriateness of antimicrobial therapy in suspected sepsis: a randomized controlled trial.
  Rashidzada Z, Cairns KA, Peel TN, Jenney AW, Doyle JS, Dooley MJ, Cheng AC
  JAC Antimicrob Resist. 2021 Aug; 3(3):dlab097
• A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
  Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N; EC Partnership
  J Viral Hepat. 2021 Aug; 28(11):1624-1634
• Routine testing for syphilis and other bacterial sexually transmissible infections is required among people in prison.
  Harney B, Doyle J, Hellard M, Stoové M, Winter R
  Sex Transm Dis. 2021 Aug; 48(10):e153
• Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study.
  Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P; Treatment and Prevention Study group
  Harm Reduct J. 2021 Jul; 18(1):73
• "It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C.
  Walker S, Wallace J, Latham N, Saich F, Pedrana A, Hellard M, Treloar C, Marukutira T, Higgs P, Doyle J, Stoové M
  Int J Drug Policy. 2021 May; 97:103280
• Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
  Goutzamanis S, Spelman T, Harney B, Dietze P, Stoové M, Higgs P, Thompson A, Doyle JS, Hellard M; Treatment, Prevention Study group.
  J Viral Hepat. 2021 Apr; 28(7):1068-1077
• Low incidence of hepatitis C among a cohort of HIV-negative gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Melbourne, Australia, and the contribution of sexual transmission.
  Cornelisse VJ, Traeger MW, Wright EJ, Murphy D, Stoove M, Hellard M, Sacks-Davis R, Asselin J, Fairley CK, Doyle J, Sasawdeusz J
  J Acquir Immune Defic Syndr. 2021 Mar; 87(4):1011-1015
• Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
  Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS
  J Viral Hepat. 2021 Feb; 28(5):771-778
• In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
  Wade AJ, Doyle JS, Draper B, Howell J, Iser D, Roberts SK, Kemp W, Thompson AJ, Hellard ME
  J Viral Hepat. 2021 Jan; 28(1):217-218
• The phases of hepatitis C elimination: achieving WHO elimination targets.
  Pedrana A, Munari S, Stoové M, Doyle J, Hellard M
  Lancet Gastroenterol Hepatol. 2021 Jan; 6(1):6-8
• The case for simplifying and using absolute targets for viral hepatitis elimination goals
  Polaris Observatory Collaborators (including Joseph Doyle)
  J Viral Hepat. 2021 Jan; 28(1):12-19
• Letter to the Editor: Recommendations for implementing hepatitis C virus care in homeless shelters: The stakeholder perspective.
  Harney B, McColl R, Pedrana A, Morrison E, Doyle J, Hellard M, Higgs P
  Hepatol Commun. 2021 Jan; 5(1):146-147
• Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study.
  Goutzamanis S, Doyle JS, Horyniak D, Higgs P, Hellard M; TAP study group
  Int J Drug Policy. 2021 Jan; 87:102983
• Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial.
  Doyle JS, van Santen DK, Iser D, Sasadeusz J, O'Reilly M, Harney B, Traeger MW, Roney J, Cutts JC, Bowring AL, Winter R, Medland N, Fairley CK, Moore R, Tee B, Asselin J, El-Hayek C, Hoy JF, Matthews GV, Prins M, Stoové MA, Hellard ME
  Clin Infect Dis. 2021 Jan; 73(7):e2164–e2172
• Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.
  Papaluca T, Roberts SK, Strasser SI, Stuart KA, Farrell G, MacQuillan G, Dore GJ, Wade AJ, George J, Hazeldine S, O'Beirne J, Wigg A, Fisher L, McGarity B, Sawhney R, Sinclair M, Thomas J, Valiozis I, Weltman M, Wilson M, Woodward A, Ahlenstiel G, Haque M, Levy M, Prewett E, Sievert W, Sood S, Tse E, Valaydon Z, Bowden S, Douglas M, New K, O'Keefe J, Hellard M, Doyle J, Stoové M, Thompson AJ
  Clin Infect Dis. 2021 Jan; 73(9):e3288-e3295

2020 (17)

• Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
  Papaluca T, Craigie A, McDonald L, Edwards A, MacIsaac M, Holmes JA, Jarman M, Lee T, Huang H, Chan A, Lai M, Sundararajan V, Doyle JS, Hellard M, Stoove M, Howell J, Desmond P, Iser D, Thompson A
  PLoS One. 2020 Nov; 15(11):e0242101
• Population patterns in Alcohol Use Disorders Identification Test (AUDIT) scores in the Australian population; 2007-2016.
  O'Brien H, Callinan S, Livingston M, Doyle JS, Dietze PM
  Aust N Z J Public Health. 2020 Oct; 44(6):462-467
• Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.
  Gupta RK, Calderwood CJ, Yavlinsky A, Krutikov M, Quartagno M, Aichelburg MC, Altet N, Diel R, Dobler CC, Dominguez J, Doyle JS, Erkens C, Geis S, Haldar P, Hauri AM, Hermansen T, Johnston JC, Lange C, Lange B, van Leth F, Muñoz L, Roder C, Romanowski K, Roth D, Sester M, Sloot R, Sotgiu G, Woltmann G, Yoshiyama T, Zellweger JP, Zenner D, Aldridge RW, Copas A, Rangaka MX, Lipman M, Noursadeghi M, Abubakar I
  Nat Med. 2020 Oct; 26:1941-1949
• Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV).
  Byrne C, Radley A, Inglis SK, Beer LJZ, Palmer N, Pham MD, Healy B, Doyle JS, Donnan P, Dillon JF
  BMJ Open. 2020 Aug; 10(8):e036501
• The impact of markers of HIV infection on change in liver stiffness in people with HIV and hepatitis C virus co-infection after treatment and cure of hepatitis C.
  van Santen DK, Agius PA, Sasadeusz J, Fairley KC, Sievert W, Gane E, Iser D, O'Reilly M, Medland NA, Moore R, Hellard ME, Hoy JF, Doyle JS
  J Acquir Immune Defic Syndr. 2020 Aug; 85(5):e81-e89
• A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available.
  Gooey M, Wong E, Pedrana A, Allard N, Doyle J, Hellard M, Wade A
  Sex Health. 2020 Aug; 17(4):387-389
• Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
  Hosseini-Hooshyar S, Martinello M, Yee J, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Petoumenos K, Carson J, Dore GJ, Matthews GV; CEASE study team
  AIDS. 2020 Jul; 34(9):1347-1358
• The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
  Traeger MW, Pedrana AE, van Santen DK, Doyle JS, Howell J, Thompson AJ, El-Hayek C, Asselin J, Polkinghorne V, Membrey D, Bramwell F, Carter A, Guy R, Stoové MA, Hellard ME; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)
  PLoS One. 2020 Jun; 15(6):e0235445
• Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
  van Santen DK, Sacks-Davis R, Doyle JS, Scott N, Prins M, Hellard M
  J Viral Hepat. 2020 Mar; 27(8):770-773
• Australia needs to increase testing to achieve hepatitis C elimination.
  Scott N, Sacks-Davis R, Wade AJ, Stoové M, Pedrana A, Doyle JS, Thompson AJ, Wilson DP, Hellard ME
  Med J Aust. 2020 Mar; 212(8):365-370
• A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.
  Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N
  Int J Drug Policy. 2020 Feb; 76:102633
• Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection.
  Scott N, Snell G, Westall G, Pilcher D, Raggatt M, Walker RG, Hellard M, Peleg AY, Doyle J
  Sci Rep. 2020 Jan; 10(1):1459
• Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure.
  Stoové M, Wallace J, Higgs P, Pedrana A, Goutzamanis S, Latham N, Scott N, Treloar C, Crawford S, Doyle J, Hellard M
  Int J Drug Policy. 2020 Jan; 75:102596
• The Elimination of Hepatitis C as a Public Health Threat.
  Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C
  Cold Spring Harb Perspect Med. 2020 Jan; 10(4):a036939
• Commentary on Barre et al. (2019): Identifying remaining barriers to hepatitis C treatment in the DAA era.
  Sacks-Davis R, van Santen DK, DoyleJS
  Addiction. 2020 Jan; 115(3):583-584
• Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.
  Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, 7, 8, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV; CEASE study team
  Clin Infect Dis. 2020 Jan; 71(6):1502-1510
• Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
  Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
  Clin Infect Dis. 2020 Jan; 70(9):1900-1906

2019 (18)

• Retreatment with Elbasvir, Grazoprevir, Sofosbuvir +/- Ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
  Papaluca T, Sinclair M, Gow P, Pianko S, Sievert W, Arachchi N, Cameron K, Bowden S, O'Keefe J, Doyle J, Stoove M, Hellard M, Iser D, Thompson A
  Liver Int. 2019 Dec; 39(12):2285-2290
• Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs.
  Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade-Nwulia OO, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R
  Liver Int. 2019 Dec; 39(12):2244-2260
• Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia
  Papalucaa T, .O’Keefe J, Bowden S, Doyle JS, Stoové M, Hellard M, Thompson AJ
  J Clin Virol. 2019 Oct; 120:84-87
• Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia.
  Harney BL, Whitton B, Lim C, Paige E, McDonald B, Nolan S, Pemberton D, Hellard ME, Doyle JS
  Int J Drug Policy. 2019 Oct; 72:195-198
• Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department.
  Hutton J, Doyle J, Zordan R, Weiland T, Cocco A, Howell J, Iser S, Snell J, Fry S, New K, Sloane R, Jarman M, Phan D, Tran S, Pedrana A, Williams B, Johnson J, Glasgow S, Thompson A
  Int J Drug Policy. 2019 Oct; 72:84-90
• Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
  Williams B, Howell J, Doyle J, Thompson AJ, Draper B, Layton C, Latham N, Bramwell F, Membrey D, Mcpherson M, Roney J, Stoové M, Hellard ME, Pedrana A
  Int J Drug Policy. 2019 Oct; 72:91-98
• Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology.
  Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K
  Clin Liver Dis. 2019 Aug; 23(3):487-492
• Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients.
  Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K
  Clin Liver Dis. 2019 Aug; 23(3):493-509
• Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.
  Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K
  Clin Liver Dis. 2019 Aug; 23(3):511-519
• Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.
  Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K
  Clin Liver Dis. 2019 Aug; 23(3):521-534
• Australia’s progress towards hepatitis C elimination. Annual Report 2019
  Burnet Institute and Kirby Institute (Prepared by Wilkinson A, Edited by Margaret Hellard M, Stoové, M, Dore G, Grebely J, Pedrana A, Doyle J, Thompson A, Hajarizadeh B, Alavi M, Aitken C)
  Annual Report. 2019 Jul
• Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement.
  Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ, Howell J, Hajkowicz K, Nandurkar H, Johnston A, Bak N, Thompson AJ
  Med J Aust. 2019 Jun; 210(10):462-468
• Hepatitis C risk perceptions and attitudes towards reinfection among HIV-diagnosed gay and bisexual men in Melbourne, Australia.
  Schroeder SE, Higgs P, Winter R, Brown G, Pedrana A, Hellard M, Doyle J, Stoové M
  J Int AIDS Soc. 2019 May; 22(5):e25288
• Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
  Doyle JS, Scott N, Sacks-Davis R, Pedrana AE, Thompson AJ, Hellard ME; Eliminate Hepatitis C Partnership
  Aliment Pharmacol Ther. 2019 Mar; 49(9):1223-1229
• Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
  Latham NH, Pedrana A, Doyle JS, Howell J, Williams B, Higgs P, Thompson AJ, Hellard ME
  J Viral Hepat. 2019 Feb; 26(7):919-922
• Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.
  Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoové M, Hellard M, Iser D, Thompson A
  J Hepatol. 2019 Jan; 70(5):839-846
• Aiming for the elimination of viral hepatitis in Australia, New Zealand, the Pacific Islands and Territories: where are we now and barriers to meeting WHO targets by 2030.
  Howell J, Pedrana A, Cowie BC, Doyle J, Getehun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME
  J Gastroenterol Hepatol. 2019 Jan; 34(1):40-48
• Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
  Goutzamanis S, Doyle J, Higgs P, Hellard M
  J Viral Hepat. 2019 Jan; 26(2):218-223

2018 (9)

• Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
  Scott N, Sacks-Davis R, Pedrana A, Doyle J, Thompson A, Hellard M
  J Viral Hepat. 2018 Jul; 25(12):1472-1480
• Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
  Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
  Trials. 2018 Jul; 19(1):383
• Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment?
  Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME
  Expert Rev Anti Infect Ther. 2018 May; 16(5):411-422
• Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: a qualitative study.
  Goutzamanis S, Doyle JS, Thompson A, Dietze P, Hellard M, Higgs P; TAP study group.
  BMC Infect Dis. 2018 Apr; 18(1):151
• Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens.
  Stepanova M, Thompson A, Doyle J, Younossi I, de Avila L, Younossi ZM
  J Infect Dis. 2018 Apr; 217(17):1033-1043
• Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.
  Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME
  J Int AIDS Soc. 2018 Apr; 21 Suppl 2:e25051
• Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access.
  Scott N, Hainsworth SW, Sacks-Davis R, Pedrana A, Doyle J, Wade A, Hellard M
  J Virus Erad. 2018 Apr; 4(2):108-114
• Effects of Pre-exposure Prophylaxis for the Prevention of HIV Infection on Sexual Risk Behavior in Men Who Have Sex with Men: A Systematic Review and Meta-analysis.
  Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, Stoové MA
  Clin Infect Dis. 2018 Mar; 67(5):676-686
• Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour.
  Scott N, Stoové M, Wilson DP, Keiser O, El-Hayek C, Doyle J, Hellard M
  J Int AIDS Soc. 2018 Jan; 21(1):e25059

2017 (6)

• Pathways to the elimination of hepatitis C: prioritising access for all.
  Pedrana AE, Sacks-Davis R, Doyle JS, Hellard ME
  Expert Rev Clin Pharmacol. 2017 Oct; 10(10):1023-1026
• Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
  Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME
  Int J Drug Policy. 2017 Sep; 47:107-116
• New hepatitis C antiviral treatments eliminate the virus.
  Doyle JS, Thompson AJ, Higgs P, Stoove M, Dietze PM, Hellard ME
  Lancet. 2017 Jul; 390(10092):358-359
• Injecting drug use in low and middle income countries: opportunities to improve care and prevent harm.
  O'Keefe D, Stoové M, Doyle J, Dietze P, Hellard M.
  J Viral Hepat. 2017 Jun; 24(9):714-724
• A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy.
  Wade A, Draper B, Doyle J, Allard N, Grinzi P, Thompson A, Hellard M
  Aust Fam Physician. 2017 Apr; 46(4):235-240
• Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
  Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME
  Gut. 2017 Mar; 66(8):1507-1515

2016 (7)

• Direct-acting antiviral treatment for HCV.
  Goutzamanis S, Doyle J, Thompson A, Hellard M, Higgs P
  Lancet Infect Dis. 2016 Dec; 16(12):1325-6
• Field engagement further facilitates hepatitis B vaccination completion: Letter in response to: Day et al. (in press).
  Higgs P, Doyle J, Luppi J, Dietze P, Hellard M
  J Clin Virol. 2016 Jul; 82:64-65
• Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.
  Doyle JS, Grebely J, Spelman T, Alavi M, Matthews GV, Thompson AJ, Dore GJ, Hellard ME; ATAHC Study Group.
  PLoS One. 2016 Jun; 11(6):e0150655
• Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks.
  Hellard M, Sacks-Davis R, Doyle J
  J Epidemiol Commun Health. 2016 Jun; 70:1151-1154
• A systematic review of community based hepatitis C treatment.
  Wade AJ, Veronese V, Hellard ME, Doyle JS.
  BMC Infect Dis. 2016 May; 16(1):202
• Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
  Scott N, Iser D, Thompson A, Doyle J, Hellard M
  J Gastroenterol Hepatol. 2016 Feb; 31(4):872-882
• HIV and Sexual Risk Among Men Who Have Sex With Men and Women in Asia: A Systematic Review and Meta-Analysis.
  Bowring AL, Veronese V, Doyle JS, Stoové M, Hellard M
  AIDS Behav. 2016 Jan; 20(10):2243-2265

2015 (5)

• The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
  Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME
  PLoS One. 2015 Nov; 10(11):e0142770
• Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
  Doyle JS, Deterding K, Grebely J, Wedemeyer H, Sacks-Davis R, Spelman T, Matthews G, Rice TM, Morris MD, McGovern BH, Kim AY, Bruneau J, Lloyd AR, Page K, Manns MP, Hellard ME, Dore GJ and the InC3 Study Group.
  J Viral Hepat. 2015 Jun; 22(12):1020-1023
• Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis.
  Trauer JM, Qian MY, Doyle JS, W Rajaratnam SM, Cunnington D
  Ann Intern Med. 2015 Jun; 163(3):191-204
• Global policy and access to new hepatitis C therapies for people who inject drugs
  Doyle JS, Aspinall EJ, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME
  Int J Drug Policy. 2015 Jun; 26(11):1064-1071
• Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.
  Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, Nguyen T, Falck-Ytter Y, Morgan RL, Smith B, Stoové M, Wiktor SZ, Hutchinson S
  Eur J Epidemiol. 2015 Feb; 30(2):115-129

2014 (6)

• Effects of HIV antiretroviral therapy on sexual and injecting risk-taking behaviour: a systematic review and meta-analysis.
  Doyle JS, Degenhardt L, Pedrana AE, McBryde ES, Guy R, Stoové MA, Weaver E, Grulich AE, Lo YR, Hellard M
  Clin Infect Dis. 2014 Aug; 59(10):1483-1494
• A systematic review of immediate HCV RNA testing following HCV Antibody compared with HCV RNA testing at time of assessment for HCV therapy.
  Hall K, Sacks-Davis R, Doyle J, Aspinall E, Hutchinson S, Hellard M
  Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2014 Jul
• Latent tuberculosis screening using interferon-gamma release assays in an Australian HIV-infected cohort: is routine testing worthwhile?
  Doyle JS, Bissessor M, Denholm JT, Ryan N, Fairley CK, Leslie DE
  J Acquir Immune Defic Syndr. 2014 Jan; 66(1):48-54
• Eradication of hepatitis C infection: The importance of targeting people who inject drugs.
  Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E
  Hepatology. 2014 Jan; 59(2):366-369
• Interferon-free hepatitis C treatment: one pill to fit all?
  Hellard ME, Doyle J
  Lancet. 2014 Jan; 383(9916):491-492
• Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis.
  Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, Palmateer N, Doyle JS, Hellard ME, Hutchinson SJ
  Int J Epidemiol. 2014 Jan; 43(1):235-248

2013 (9)

• Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis.
  Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME
  Clin Infect Dis. 2013 Aug; 57 Suppl 2:S80-S89
• Direct acting antiviral therapy versus pegylated interferon and ribavirin treatment for chronic hepatitis C infection: a meta-analytical systematic review.
  Doyle JS, Thompson AJ, Aspinall EJ, Hutchinson SJ, Hellard ME
  Technical Report for the World Health Organisation, Global Hepatitis Programme. 2013 Jul
• A systematic review of the effectiveness of antiviral treatment compared with no treatment for chronic HCV.
  Doyle JS, Malandkar S, Aspinall EJ, Hall K, Hutchinson SJ, Hellard ME
  Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
• A systematic review and meta-analysis of targeted HCV antibody testing interventions.
  Aspinall EJ, Doyle JS, Corson S, Hunt D, Hellard ME, Hutchinson SJ
  Technical Report for World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
• A systematic review of interventions to reduce alcohol consumption among individuals with chronic HCV infection.
  Hunt D, Doyle JS, Aspinall EJ, Hutchinson SJ, Hellard ME
  Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
• Pegylated interferon plus ribavirin versus standard interferon plus ribavirin for chronic hepatitis C infection: a meta-analytical systematic review.
  Quinn B, Doyle JS, Howell J, Chow SM, Aspinall EJ, Hutchinson SJ, Hellard ME
  Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
• Beyond injecting drug use: investigation of a Victorian cluster of hepatitis C among HIV-infected men who have sex with men.
  Mahony AA, Donnan EJ, Lester RA, Doyle JS, Knox J, Tracy SL, Bowden S, Sasadeusz JJ
  Med J Aust. 2013 Mar; 198(4):210-214
• Current and emerging antiviral treatments for hepatitis C infection.
  Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME
  Br J Clin Pharmacol. 2013 Mar; 75(4):931-43
• Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
  Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME
  J Gastroenterol Hepatol. 2013 Jan; 28(4):707-16

2012 (2)

• The role of viral and host genetics in natural history and treatment of chronic HCV infection.
  Doyle JS, Hellard ME, Thompson AJ
  Best Pract Res Clin Gastroenterol. 2012 Aug; 26(4):413-427
• Murray Valley encephalitis: a review of clinical features, diagnosis and treatment.
  Knox J, Cowan RU, Doyle JS, Ligtermoet MK, Archer JS, Burrow JN, Tong SY, Currie BJ, Mackenzie JS, Smith DW, Catton M, Moran RJ, Aboltins CA, Richards JS
  Med J Aust. 2012 Mar; 196(5):322-326

2011 (3)

• Epidemiology of infections acquired in intensive care units.
  Joseph S Doyle, Kirsty L Buising, Karin A Thursky, Leon J Worth, Michael J Richards
  Semin Respir Crit Care Med. 2011 Apr; 32(2):115-138
• Mumps presenting as epididymo-orchitis among young travellers: under-recognition, missed diagnoses and transmission risks.
  Joseph S Doyle, Emma K Paige, Denis W Spelman
  Med J Aust. 2011 Mar; 194(6):317-318
• Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy.
  Doyle JS, Campbell E, Fuller A, Spelman DW, Cameron R, Malham G, Gin D, Lewin SR
  J Neurosurg. 2011 Feb; 114(2):458-462

News Articles (37)

2021 (3)

• IAS award for Burnet researcher
• New Action Plan for hepatitis elimination
• Your vaccine questions answered

2020 (7)

• NHMRC support for Burnet hepatitis research
• Burnet showcased to a Global audience
• Community rules on World Hepatitis Day
• MRFF funding for Burnet COVID research
• Burnet appointments to COVID-19 Taskforce
• Testing rate fall leaves thousands of Australians at risk of hepatitis C
• Burnet's COVID-19 self-isolation study

2019 (7)

• NHMRC Ideas Grants
• Tall Poppy award for Dr Joseph Doyle
• Dr Joseph Doyle wins Club Melbourne Fellowship
• First national hepatitis report reveals progress
• Dr Joseph Doyle a nominee for prestigious Fellowship
• Primary healthcare effort needed to achieve hep C elimination
• Hepatitis C treatment in primary care crucial to elimination

2018 (4)

• Ned's award for research excellence
• EC Australia: The missing link to hepatitis C elimination
• Hepatitis elimination efforts in great hands
• Scholarships for Burnet alumni

2017 (4)

• Burnet World Hepatitis Day Symposium
• Hep C treatment decline prompts new call out
• The case for new hepatitis C treatments
• Dr Joseph Doyle is 2017 Gust-McKenzie Medallist

2016 (9)

• Hep C: Elimination is the Goal
• Burnet launches Eliminate Hep C strategy
• 2020 vision for Hep C elimination
• Hep C co-EC study showcased at AIDS 2016
• NHMRC grant to assist hepatitis C research
• Australia a potential world leader to eliminate hepatitis C
• Historic partnership aims to end hep C within a decade
• Landmark day with listing of hepatitis C drugs on PBS scheme
• TAP Study: A key to hepatitis C elimination

2014 (3)

• Travel Awards to enhance Burnet research
• AIDS 2014: Burnet Institute research showcased
• First-ever hepatitis C treatment guidelines released